Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HVEM drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HVEM ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View HVEM Products |
| Gene Delivery | HVEM Promise-ORF / Lentivirus Full-length ORF for stable cell line development and conformation-dependent assays. |
View HVEM Products |
| Benchmark Ab | Anti-HVEM Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View HVEM Products |
| Validator | HVEM siRNA Set For target knockdown verification and specificity profiling. |
View HVEM Products |
| Related Target A | BTLA Co-inhibitory ligand interacting with HVEM to suppress T-cell activation. Key target for checkpoint combination therapies. |
View BTLA Products |
| Related Target B | LIGHT (TNFSF14) Co-stimulatory ligand competing for HVEM binding. Crucial for understanding bidirectional signaling. |
View LIGHT Products |
| Related Target C | CD160 Alternative co-inhibitory ligand that binds to the same cysteine-rich domains of HVEM. |
View CD160 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Binding Complexity (BTLA vs. LIGHT vs. CD160) | High-purity, monomeric and dimeric HVEM ECD proteins verified by SEC-HPLC to ensure accurate affinity measurements. |
| Conformation-Sensitive Screening | Lentivirus premade particles optimized for stable cell line generation, preserving native membrane-bound structure for flow cytometry. |
| Lack of Benchmarking Controls | Clinical-grade biosimilar benchmark antibodies available for direct assay comparison. |
| Off-Target Verification | Complete TNFRSF subfamily protein panel available for cross-reactivity screening. |
Live HVEM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HVEM (TNFRSF14) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to bispecific antibodies and combination strategies targeting the HVEM-BTLA axis. As a unique bidirectional molecular switch that can deliver both stimulatory (via LIGHT) and inhibitory (via BTLA/CD160) signals, therapeutic intervention requires precise molecular targeting. The next wave of R&D is focused on selectively blocking the co-inhibitory HVEM-BTLA interaction while preserving or enhancing the co-stimulatory HVEM-LIGHT pathway, particularly in cold tumors and lymphoma microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | HiFiBiO Therapeutics, Academic Institutions | Solid Tumors, Lymphomas | Ligand-blocking assays (Requires high-purity HVEM, BTLA, and LIGHT proteins) |
| Bispecific Antibodies (e.g., HVEM x BTLA) | Biotech Innovators | Refractory Solid Tumors, Autoimmune Diseases | Simultaneous binding kinetics (Requires stable cell lines via Lentivirus delivery) |
| Recombinant Fusion Proteins | Clinical Stage Biopharma | Inflammatory Bowel Disease (IBD), GvHD | pH-dependent binding assays (Requires sequence-verified ECD-Fc proteins) |